Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Aurinia Pharmaceuticals Inc. < Previous 1 2 3 Next > Aurinia Announces 2024 Annual General Meeting Results June 14, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 June 05, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce June 04, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Provides Update on Proxy Statement June 03, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Will Attend 2024 Jefferies Global Healthcare Conference May 30, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024 May 14, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024 May 09, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference May 07, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results May 02, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month May 01, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program April 30, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference April 16, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024 April 15, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference April 09, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program February 29, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia to Participate in Upcoming Investor Healthcare Conferences February 27, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value February 15, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024 February 05, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results January 05, 2024 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Submits IND Application to US Food & Drug Administration for AUR 200 December 20, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan November 13, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023 November 07, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis November 02, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results November 02, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis October 26, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023 October 19, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR) October 13, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital September 21, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines August 21, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results August 03, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.